ArticlePsychopharmacology2026
Functional crosstalk between neuropeptide FF system and N-type voltage-gated calcium channels in ziconotide-mediated antinociception in mice.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ziconotide is a selective, potent, and reversible blocker of neuronal N-type voltage-gated calcium channels (VGCCs). Neuropeptide FF (NPFF) belongs to the opioid-modulating peptide family and plays a vital role in pain control through interactions with the opioid system. NPFF receptor agonists inhibit N-type VGCCs via G-protein coupling mechanism. This study focuses on whether intrathecal administration of NPFF influences ziconotide-induced antinociception. The effects of NPFF and related peptides on the antinociceptive activities of ziconotide were examined in male Kunming mice. Results showed that NPFF significantly enhanced ziconotid-induced analgesia in a dose-dependent manner in both the mouse tail-flick test and the visceral pain model. Additionally, treatment with the NPFF receptor selective antagonist RF9 markedly reduced the ziconotide-modulating effects of NPFF and related peptides in the pain models, whereas treatment with the opioid receptors antagonist naloxone had no effect. Co-administration of ziconotide with NPFF and related peptides from day 1 to day 8 produced insignificant differences in analgesic sensitivity, indicating that NPFF and related peptides did not induce tolerance to ziconotide following chronic co-treatment. These data provide the first in vivo evidence of a functional interaction between the NPFF system and N-type VGCCs, demonstrating that spinal NPFF receptor activation interferes with ziconotide-mediated antinociception. Thus, combining ziconotide with NPFF agonists may represent a valuable strategy for pain management.
Indexed as
Identifiers
41910723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.